CHIMERIX INC Form SC 13G February 14, 2014

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

CHIMERIX, INC.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

16934W106

(CUSIP Number)

December 31, 2013

(Date of Event That Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o Rule 13d-1(b)

o Rule 13d-1(c)

x Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(1)	Names of Reporting Persons. Alta BioPharma Partners III, L.P.		
(2)	Check the Appropriat	e Box if a Member of a C	Group
	(a)	0	
	(b)	Х	
(3)	SEC Use Only		
(4)	Citizenship or Place o Delaware	of Organization	
Noushan af	(5)		Sole Voting Power 1,696,346 (a)
Number of			
Shares	(6)		Shared Voting Power
Beneficially			-0-
Owned by			
Each	(7)		Sole Dispositive Power
Reporting			1,696,346 (a)
Person With			
	(8)		Shared Dispositive Power -0-
(9)	Aggregate Amount Be 1,696,346 (a)	eneficially Owned by Ea	ch Reporting Person
(10)	Check if the Aggregate Amount in Row (9) Excludes Certain Shares o		
(11)	Percent of Class Repr 6.39% (b)	resented by Amount in Ro	ow (9)
(12)	Type of Reporting Per PN	rson	

⁽a) Alta BioPharma Partners III, L.P. (ABPIII) has sole voting and dispositive control over 1,570,183 shares of common stock (Common Stock) and warrants to purchase 126,163 shares of Common Stock of Chimerix, Inc. (the Issuer), except that Alta BioPharma Management III, LLC (ABMIII), the general partner of ABPIII, and Farah Champsi (Champsi), and Edward Hurwitz (Hurwitz), and Edward Penhoet (Penhoet), directors of ABMPIII, may be deemed to share the right to direct the voting and dispositive control over such stock. Additional information about ABPIII is set forth in Attachment A hereto.

⁽b) The percentage set forth in row (11) is based on an aggregate of 26,420,39 shares of Common Stock outstanding as of November 1, 2013 as reported in the Issuer s 10-Q filing for the quarter ended September 30, 2013.

Edgar Filing: CHIMERIX INC - Form SC 13G

CUSIP No. 16934W106

(1)	Names of Reporting Persons. Alta BioPharma Partners III GmbH & Co. Beteiligungs KG			
(2)	Check the Appropriate Box if a Member of a Group			
	(a)	0		
	(b)	Х		
(3)	SEC Use Only			
(4)	(4) Citizenship or Place of Organization			
	Germany			
	(5)			
	(5)		Sole Voting Power 113,924 (c)	
Number of			115,924 (0)	
Shares	(6)		Shared Voting Power	
Beneficially			-0-	
Owned by				
Each	(7)		Sole Dispositive Power	
Reporting Person With			113,924 (c)	
	(8)		Shared Dispositive Power	
			-0-	
(9)			ng Person	
	113,924 (c)			
(10)	Check if the Aggregate Amount in Row (9) Excludes Certain Shares o			
(11)	Percent of Class Represented by Amount in Row (9)			
	0.43% (b)			
(12)	т (р. (^с . р.			
(12)	Type of Reporting Person PN			
	117			

⁽c) Alta BioPharma Partners III GmbH & Co. Beteiligungs KG (ABPIIIKG) has sole voting and dispositive control over 105,452 shares of Common Stock and warrants to purchase 8,472 shares of Common Stock, except that Alta BioPharma Management III, LLC (ABMIII), the managing limited partner of ABPIIIKG, Champsi, Penhoet, and Hurwitz, directors of ABMPIII, may be deemed to share the right to direct the voting and dispositive control over such stock. Additional information about ABPIIIKG is set forth in Attachment A hereto.

³

(1)	Names of Reporting Persons. Alta BioPharma Management III, LLC		
(2)	Check the Appropriate Box if a	a Member of a Group	
	(a)	0	
	(b)	X	
(3)	SEC Use Only		
(4)	Citizenship or Place of Organiz Delaware	zation	
Number of	(5)		Sole Voting Power -0-
Shares Beneficially Owned by	(6)		Shared Voting Power 1,810,270 (d)
Each Reporting Person With	(7)		Sole Dispositive Power -0-
	(8)		Shared Dispositive Power 1,810,270 (d)
(9) Aggregate Amount Beneficially Owned by Each Reporting Person 1,810,270 (d)		g Person	
(10)	(10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares o		
(11)	Percent of Class Represented by Amount in Row (9) 6.82% (b)		
(12)	Type of Reporting Person OO		

⁽d) ABMIII shares voting and dispositive power over the 1,570,183 shares of Common Stock and warrants to purchase 126,163 shares of Common Stock beneficially owned by ABPIII and the 105,452 shares of Common Stock and warrants to purchase 8,472 shares of Common Stock beneficially owned by ABPIIIKG. Additional information about ABMIII is set forth in Attachment A hereto.

⁴

(1)	Names of Reporting Persons. Alta Embarcadero BioPharma Partners III, LLC		
(2)	Check the Appropriate Box i	f a Member of a Group	
	(a)	0	
	(b)	Х	
(3)	SEC Use Only		
(4)	Citizenship or Place of Organization California		
Number of	(5)		Sole Voting Power 41,804 (e)
Shares	(6)		Shared Voting Power
Beneficially			-0-
Owned by			-0-
Each	(7)		Sole Dispositive Power
Reporting			41,804 (e)
Person With			, (-)
	(8)		Shared Dispositive Power
			-0-
(9)	(9) Aggregate Amount Beneficially Owned by Each Reporting Person 41,804 (e)		
(10)	Check if the Aggregate Amount in Row (9) Excludes Certain Shares o		
(11)	Percent of Class Represented by Amount in Row (9) 0.16% (b)		
(12)	Type of Reporting Person OO		

⁽e) Alta Embarcadero BioPharma Partners III, LLC (AEBPIII) has sole voting and dispositive control over 38,695 shares of Common Stock and warrants to purchase 3,109 shares of Common Stock, except that Champsi, Penhoet, and Hurwitz, managing directors of AEBPIII, may be deemed to share the right to direct the voting and dispositive control over such stock. Additional information about AEBPIII is set forth in Attachment A hereto.

⁵

(1)	Names of Reporting Persons. Farah Champsi		
(2) Check the Appropriate Box if a Member of a Group			
	(a)	0	
	(b)	Х	
(3)	SEC Use Only		
(4)	Citizenship or Place of Orga United States	anization	
	Sinted States		
	(5)		Sole Voting Power -0-
Number of			
Shares Beneficially Owned by	(6)		Shared Voting Power 1,852,074 (h)
Each	(7)		Sole Dispositive Power
Reporting	(r)		-0-
Person With			
	(8)		Shared Dispositive Power 1,852,074 (h)
(9)	Aggregate Amount Benefic 1,852,074 (h)	ially Owned by Each Repor	ting Person
(10)	Check if the Aggregate Amount in Row (9) Excludes Certain Shares o		
(11)	Percent of Class Represented by Amount in Row (9) 6.97% (b)		
(12)	Type of Reporting Person IN		

⁽h) Champsi shares voting and dispositive control over the 1,570,183 shares of common stock and warrants to purchase 126,163 shares of Common Stock beneficially owned by ABPIII, the 105,452 shares of Common Stock and warrants to purchase 8,472 shares of Common Stock beneficially owned by ABPIIIKG, and the 38,695 shares of Common Stock and warrants to purchase 3,109 shares of Common Stock beneficially owned by ABPIII. Additional information about Champsi is set forth in Attachment A hereto.

⁶

(1)	Names of Reporting Persons.		
	Edward Penhoet		
(2)	Check the Appropriate Box if a (a) (b)	a Member of a Group o x	
(3)	SEC Use Only		
(4)	Citizenship or Place of Organi United States	zation	
	(5)		Sole Voting Power -0-
Number of Shares Beneficially Owned by	(6)		Shared Voting Power 1,852,074 (i)
Each Reporting Person With	(7)		Sole Dispositive Power -0-
	(8)		Shared Dispositive Power 1,852,074 (i)
(9)	Aggregate Amount Beneficiall 1,852,074 (i)	y Owned by Each Reportin	g Person
(10)	Check if the Aggregate Amount in Row (9) Excludes Certain Shares o		
(11)	Percent of Class Represented by Amount in Row (9) 6.97% (b)		
(12)	Type of Reporting Person IN		

⁽i) Penhoet shares voting and dispositive control over the 1,570,183 shares of common stock and warrants to purchase 126,163 shares of Common Stock beneficially owned by ABPIII, the 105,452 shares of Common Stock and warrants to purchase 8,472 shares of Common Stock beneficially owned by ABPIIIKG, and the 38,695 shares of Common Stock and warrants to purchase 3,109 shares of Common Stock beneficially owned by ABPIII. Additional information about Penhoet is set forth in Attachment A hereto.

⁷

(1)	Names of Reporting Persons.		
	Edward Hurwitz		
(2)	Check the Appropriate Box if a Member of a Group (a) o (b) x		
(3)	SEC Use Only		
(4)	Citizenship or Place of Organization United States		
	(5)	Sole Voting Power -0-	
Number of Shares Beneficially Owned by	(6)	Shared Voting Power 1,852,074 (j)	
Each Reporting Person With	(7)	Sole Dispositive Power -0-	
	(8)	Shared Dispositive Power 1,852,074 (j)	
(9)	Aggregate Amount Beneficially Owned by Each Reportin 1,852,074 (j)	ng Person	
(10)	Check if the Aggregate Amount in Row (9) Excludes Certain Shares o		
(11)	Percent of Class Represented by Amount in Row (9) 6.97% (b)		
(12)	Type of Reporting Person IN		

⁽j) Hurwitz shares voting and dispositive control over the 1,570,183 shares of common stock and warrants to purchase 126,163 shares of Common Stock beneficially owned by ABPIII, the 105,452 shares of Common Stock and warrants to purchase 8,472 shares of Common Stock beneficially owned by ABPIIIKG, and the 38,695 shares of Common Stock and warrants to purchase 3,109 shares of Common Stock beneficially owned by AEBPIII. Additional information about Hurwitz is set forth in Attachment A hereto.

⁸

Item 1.				
	(a)	Name of Issuer:		
		Chimerix, Inc. (Issu		
	(b)	Address of Issuer's 2505 Meridian Parky	Principal Executive Offi	ces:
		Durham, North Caro		
		,		
Item 2.				
	(a)	Name of Person Filin	ng:	
			tners III, L.P. (ABPIII	
			nagement III, LLC (AB	
			ioPharma Partners III, L	eteiligungs KG (ABPIIIKG)
		Farah Champsi (FC		
		Edward Penhoet (E		
		Edward Hurwitz (E		
	(b)	Address of Principal		
		One Embarcadero Co San Francisco, CA	,	
	(c)	Citizenship/Place of		
		Entities:	ABPIII	Delaware
			ABMIII	Delaware
			ABPIIIKG	Germany
			AEBPIII	California
		Individuals:	FC	United States
			EP	United States
			EH	United States
	(d)	Title of Class of Sec	urities:	
		Common Stock		
	(e)	CUSIP Number:		
		16934W106		
Item 3.	Not applica	ble.		

9

Item 4 Ownership.

Shared Voting Power

Sole Dispositive Power

Shared Dispositive Power

Please see Attachment A

		ABPIII	ABMIII	ABPIIIKG	AEBPIII
(a)	Beneficial Ownership	1,696,346	1,810,270	113,924	41,804
(b)	Percentage of Class	6.39%	6.82%	0.43%	0.16%
(c)	Sole Voting Power	1,696,346	-0-	113,924	41,804
	Shared Voting Power	-0-	1,810,270	-0-	-0-
	Sole Dispositive Power	1,696,346	-0-	113,924	41,804
	Shared Dispositive Power	-0-	1,810,270	-0-	-0-
		FC	EP	ЕН	
(a)	Beneficial Ownership	1,852,074	1,852,074	1,852,074	
(b)	Percentage of Class	6.97%	6.97%	6.97%	
(c)	Sole Voting Power	-0-	-0-	-0-	

1,852,074

1,852,074

-0-

Item	5.

Ownership of Five Percent or Less of a Class

1,852,074

1,852,074

-0-

1,852,074

1,852,074

-0-

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following o

Item 6. Not applicable.	Ownership of More than Five Percent on Behalf of Another Person
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
Not applicable.	
Item 8. No reporting person is a member of a group as de	Identification and Classification of Members of the Group fined in Section 240.13d-1(b)(1)(ii)(H) of the Act.

Item 9. Not applicable. Notice of Dissolution of Group

10

Item 10. Not applicable. Certification

EXHIBITS

A:

Joint Filing Statement

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date:

February 14, 2014

ALTA BIOPHARMA PARTNERS III, L.P.

By: Alta BioPharma Management III, LLC

By:

/s/ Farah Champsi Farah Champsi, Director

ALTA EMBARCADERO BIOPHARMA PARTNERS III, LLC

ALTA BIOPHARMA MANAGEMENT III, LLC

By:

/s/ Farah Champsi Farah Champsi, Director

ALTA BIOPHARMA PARTNERS III GMBH &CO. BETEILIGUNGS KG By: Alta BioPharma Management III, LLC

/s/ Farah Champsi

/s/ Edward Hurwitz

Edward Hurwitz

Farah Champsi, Director

By:

/s/ Farah Champsi Farah Champsi, Manager

/s/ Farah Champsi Farah Champsi

/s/ Edward Penhoet Edward Penhoet

EXHIBIT A

AGREEMENT OF JOINT FILING

We, the undersigned, hereby express our agreement that the attached Schedule 13G is filed on behalf of us.

Date:

February 14, 2014

ALTA BIOPHARMA PARTNERS III, L.P.

By: Alta BioPharma Management III, LLC

By:

/s/ Farah Champsi Farah Champsi, Director

By:

/s/ Farah Champsi Farah Champsi, Director

ALTA EMBARCADERO BIOPHARMA PARTNERS III, LLC

ALTA BIOPHARMA PARTNERS III GMBH &CO. BETEILIGUNGS KG By: Alta BioPharma Management III, LLC

ALTA BIOPHARMA MANAGEMENT III, LLC

By:

/s/ Farah Champsi Farah Champsi, Manager

/s/ Farah Champsi Farah Champsi

/s/ Edward Penhoet Edward Penhoet /s/ Farah Champsi Farah Champsi, Director

/s/ Edward Hurwitz Edward Hurwitz

12

Attachment A

Alta BioPharma Partners III, L.P. beneficially owns 1,570,183 shares of Common Stock and warrants to purchase 126,163 shares of Common Stock and exercises sole voting and dispositive control over such shares, except to the extent set forth below.

Alta BioPharma Partners III GmbH & Co. Beteiligungs KG beneficially owns 105,452 shares of Common Stock and warrants to purchase 8,472 shares of Common Stock and exercises sole voting and dispositive control over such shares, except to the extent set forth below.

Alta Embarcadero BioPharma Partners III, LLC beneficially owns 38,695 shares Common Stock and warrants to purchase 3,109 shares of Common Stock and exercises sole voting and dispositive control over such shares, except to the extent set forth below.

Alta BioPharma Management III, LLC is the general partner of Alta BioPharma Partners III, L.P. and the managing limited partner of Alta BioPharma Partners III GmbH & Co. Beteiligungs KG and may be deemed to share the right to direct the voting and dispositive control over the shares held by such fund.

Ms. Farah Champsi is a director of Alta BioPharma Management III, LLC, and a manager of Alta Embarcadero BioPharma Partners III, LLC. She may be deemed to share the right to direct the voting and dispositive control over the shares held by such funds.

Mr. Edward Hurwitz is a director of Alta BioPharma Management III, LLC, and a manager of Alta Embarcadero BioPharma Partners III, LLC. He may be deemed to share the right to direct the voting and dispositive control over the shares held by such funds.

Mr. Edward Penhoet is a director of Alta BioPharma Management III, LLC, and a manager of Alta Embarcadero BioPharma Partners III, LLC. He may be deemed to share the right to direct the voting and dispositive control over the shares held by such funds.